Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis.

Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA.

Development. 2010 Jun;137(12):2045-54. doi: 10.1242/dev.043299.

2.

Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6.

Xu J, Sankaran VG, Ni M, Menne TF, Puram RV, Kim W, Orkin SH.

Genes Dev. 2010 Apr 15;24(8):783-98. doi: 10.1101/gad.1897310.

3.

Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer.

Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, Massie CE, Vowler SL, Eldridge M, Carroll JS.

Genes Dev. 2010 Jan 15;24(2):171-82. doi: 10.1101/gad.552910.

4.

Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.

Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R.

Mod Pathol. 2010 Feb;23(2):205-12. doi: 10.1038/modpathol.2009.159. Epub 2009 Nov 6.

5.

Expression of androgen receptors in primary breast cancer.

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS.

Ann Oncol. 2010 Mar;21(3):488-92. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.

PMID:
19887463
6.

CEAS: cis-regulatory element annotation system.

Shin H, Liu T, Manrai AK, Liu XS.

Bioinformatics. 2009 Oct 1;25(19):2605-6. doi: 10.1093/bioinformatics/btp479. Epub 2009 Aug 18.

PMID:
19689956
7.

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD.

Cancer Res. 2009 Aug 1;69(15):6131-40. doi: 10.1158/0008-5472.CAN-09-0452. Epub 2009 Jul 28.

8.

Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M.

Cell. 2009 Jul 23;138(2):245-56. doi: 10.1016/j.cell.2009.04.056.

9.

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Baselga J, Swain SM.

Nat Rev Cancer. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Epub 2009 Jun 18. Review.

PMID:
19536107
10.

Supervised risk predictor of breast cancer based on intrinsic subtypes.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS.

J Clin Oncol. 2009 Mar 10;27(8):1160-7. doi: 10.1200/JCO.2008.18.1370. Epub 2009 Feb 9.

11.

Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers.

Eeckhoute J, Lupien M, Meyer CA, Verzi MP, Shivdasani RA, Liu XS, Brown M.

Genome Res. 2009 Mar;19(3):372-80. doi: 10.1101/gr.084582.108. Epub 2009 Jan 7.

12.

Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.

Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L.

Nat Chem Biol. 2009 Feb;5(2):100-7. doi: 10.1038/nchembio.137. Epub 2009 Jan 4.

13.

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.

Cancer Res. 2008 Jul 15;68(14):5878-87. doi: 10.1158/0008-5472.CAN-08-0380.

14.

FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M.

Cell. 2008 Mar 21;132(6):958-70. doi: 10.1016/j.cell.2008.01.018.

15.

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD.

Lancet Oncol. 2007 Dec;8(12):1071-1078. doi: 10.1016/S1470-2045(07)70345-5. Epub 2007 Nov 19. Retraction in: Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD. Lancet Oncol. 2011 Feb;12(2):116.

PMID:
18024211
16.

A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.

Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M.

Mol Cell. 2007 Aug 3;27(3):380-92.

17.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM.

Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.

18.

Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.

Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, Chinnaiyan AM.

Neoplasia. 2007 May;9(5):443-54.

20.

Wnt signaling pathway in mammary gland development and carcinogenesis.

Turashvili G, Bouchal J, Burkadze G, Kolar Z.

Pathobiology. 2006;73(5):213-23. Review.

PMID:
17314492

Supplemental Content

Support Center